Future of IIM TreatmentPreview
Open in TheBrain

Rituximab

In idiopathic inflammatory myopathies (IIM), the most “established” prospective trial dataset for rituximab remains the RIM trial (adult PM, adult DM, and JDM) using a randomized placebo-phase design in which all participants ultimately received rituximab; accordingly, the primary analysis compared time-to-improvement between “early” vs “late” rituximab groups rather than rituximab vs true placebo throughout. Among 200 randomized patients, there was no difference in median time to achieving the IMACS Definition of Improvement (DOI) (20.0 vs 20.2 weeks; P=0.74), yet 161/195 (83%) of analyzable participants ultimately met DOI over 44 weeks, with core set measures improving in both groups—supporting a clinically meaningful signal in refractory disease, but also highlighting the limitations of the design for proving superiority at the chosen endpoint. [1]

RIM-based analyses identified which phenotypes are most likely to improve. In a multivariable time-to-event model (n=195), myositis autoantibody status strongly associated with shorter time to improvement: anti-synthetase *(primarily anti-Jo-1) HR 3.08, anti-Mi-2 HR 2.5 (both *p<0.01), while the autoantibody-negative subset had poorer improvement; *lower baseline damage and JDM *also predicted improvement (effects attenuated by ~week 20). [2]

At the synthesis level, meta-analyses pooling mostly observational cohorts plus the RIM RCT show broadly consistent effectiveness signals: one 2025 systematic review/meta-analysis (17 studies; 362 patients) reported an overall pooled response ~70% (PM 69%, DM 67%, antisynthetase syndrome 70%, IMNM 86%), with infusion reactions ~18.5% and infections ~12.4%; response rates were similar between common induction regimens (1 g day 0/14 vs 375 mg/m² weekly ×4). [3] Another 2022 meta-analysis (26 studies) found an overall response around 65%, with organ-specific responses highest for skin (~81%), then lungs (~65%), then muscle (~59%), and reported severe adverse events and infections in the single-digit range in pooled estimates (interpret cautiously given heterogeneity and selection). [4]

“Preliminary” (but clinically influential) IIM evidence includes targeted prospective cohorts in homogeneous subgroups and organ-dominant disease. In an open-label phase II study of refractory anti-synthetase syndrome (n=12; 10 completed), the primary muscle endpoint was met by 2/10, but 7/10 had meaningful MMT10 gains; CK fell (median 399 → 74.5 IU/L), steroids decreased substantially (median 52.5 → 9 mg/day), and several patients reduced concomitant immunosuppression—suggesting steroid-sparing and multi-organ signals while underscoring the need for controlled trials. [5]

For IIM-associated ILD (an outcome driver in many IIM subsets), the RECITAL randomized controlled phase 2b *trial in severe/progressive CTD-ILD (including IIM) showed rituximab was not superior to cyclophosphamide* for the primary endpoint at 24 weeks (adjusted difference −40 mL FVC, 95% CI −153 to 74; p=0.49), but both groups improved (~+97–99 mL mean FVC), quality-of-life improved, steroid exposure was lower with rituximab, and adverse events were numerically fewer—supporting rituximab as a reasonable IV alternative when ILD severity warrants escalation. [6]

References (linked)

  1. Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65(2):314-324. PubMed: https://pubmed.ncbi.nlm.nih.gov/23124935/
  2. Aggarwal R, Bandos A, Reed AM, et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol. 2014;66(3):740-749. PubMed: https://pubmed.ncbi.nlm.nih.gov/24574235/ (Free full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC3987896/)
  3. Otalora Rojas L, Ramsubeik K, Sanchez-Ramos L, et al. Rituximab treatment in adult patients with idiopathic inflammatory myositis: a systematic review and meta-analysis. J Clin Rheumatol. 2025;31(1):33-39. PubMed: https://pubmed.ncbi.nlm.nih.gov/39527803/
  4. Zhen C, Hou Y, Zhao B, et al. Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis. Front Immunol. 2022;13:1051609. PubMed: https://pubmed.ncbi.nlm.nih.gov/36578492/ (Free full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC9791086/)
  5. Allenbach Y, Guiguet M, Rigolet A, et al. Efficacy of rituximab in refractory inflammatory myopathies associated with anti-synthetase auto-antibodies: an open-label, phase II trial. PLoS One. 2015. PubMed: https://pubmed.ncbi.nlm.nih.gov/26539981/ (Free full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC4634756/)
  6. Maher TM, Tudor VA, Saunders P, et al. Rituximab versus intravenous cyclophosphamide in patients with CTD-associated ILD in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med. 2023;11(1). PubMed: https://pubmed.ncbi.nlm.nih.gov/36375479/
  7. ClinicalTrials.gov. Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis (RIM). NCT00106184. https://clinicaltrials.gov/study/NCT00106184